← Back to Search

Selective Serotonin Reuptake Inhibitor

Citalopram for Parkinson's Disease

Phase 2
Waitlist Available
Led By Vikas Kotagal, MD
Research Sponsored by University of Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects with a Parkinson Disease (PD) diagnosis based on the United Kingdom Parkinson's Disease Society Brain Bank Research Center clinical diagnostic criteria
Age 65 years or greater
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to month 26
Awards & highlights

Study Summary

This trial will test whether citalopram can alter the build-up of toxic amyloid-beta plaques in the visuospatial cortex of the brain linked to visuospatial cognitive impairment in PD.

Who is the study for?
This trial is for people aged 65 or older with Parkinson's Disease, having specific disease severity scores (HY 2.0 to 3.0). They must not have used antidepressants in the past year, have no major brain damage on imaging, no life-threatening illnesses, and cannot be pregnant or breastfeeding.Check my eligibility
What is being tested?
The study tests if Citalopram can slow down the build-up of harmful plaques in a part of the brain affecting vision-related cognition in Parkinson's patients over a period of 26 months compared to a placebo.See study design
What are the potential side effects?
Citalopram may cause side effects like nausea, sleepiness, dry mouth, increased sweating, trembling and sexual problems. It might also affect heart rhythm or lead to emotional changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Parkinson's Disease.
Select...
I am 65 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to month 26
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to month 26 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in visuospatial cortex PiB distribution volume ratio (DVR)
Secondary outcome measures
Change in Benton Judgement of Line Orientation (JOLO) test score
Change in Montreal Cognitive Assessment (MoCA) score

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CitalopramExperimental Treatment1 Intervention
20mg daily
Group II: PlaceboPlacebo Group1 Intervention
matching placebo pills
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Citalopram 20mg
2018
N/A
~130

Find a Location

Who is running the clinical trial?

University of MichiganLead Sponsor
1,795 Previous Clinical Trials
6,373,878 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,669 Previous Clinical Trials
28,005,056 Total Patients Enrolled
Vikas Kotagal, MDPrincipal Investigator - University of Michigan
University of Michigan

Media Library

Citalopram (Selective Serotonin Reuptake Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04497168 — Phase 2
Parkinson's Disease Research Study Groups: Placebo, Citalopram
Citalopram (Selective Serotonin Reuptake Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04497168 — Phase 2
Parkinson's Disease Clinical Trial 2023: Citalopram Highlights & Side Effects. Trial Name: NCT04497168 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants currently being accepted for this research endeavor?

"This experimental trial, initially posted on April 1st 2021 and last updated March 30th 2022 according to clinicaltrials.gov, is still recruiting participants."

Answered by AI

Does the Food and Drug Administration endorse Citalopram 20mg?

"Our organisation determined that Citalopram 20mg is a level 2 drug due to the existing evidence regarding its safety, but no record of its efficacy."

Answered by AI

Is Citalopram 20mg typically administered to remedy any particular ailments?

"Citalopram 20mg is an efficacious treatment for panic attacks, diabetic neuralgia, and premenstrual dysphoric disorder."

Answered by AI

How many individuals are enrolled in this research endeavor?

"Affirmative. The clinical trial, initially posted in April 2021, is still recruiting patients and the info on clinicaltrials.gov has been recently updated at the end of March 2022. 58 participants are needed from 1 medical centre."

Answered by AI

Who else is applying?

What state do they live in?
California
What site did they apply to?
University of Michigan
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease
Vikas Kotagal 2021. "Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04497168.
All > Parkinsons Disease > Parkinson Disease
~22 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top